CLINICAL TRIAL: PI &PHARMACOKINETIC SINGLE AGENT STUDY OF DRUG IN PTS W ADV MALI

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该I期、NCI UO 1支持的方案的目标是在晚期癌症和不同程度肝功能障碍（轻度、中度和重度）的患者组中确定帕唑帕尼的最大耐受剂量（MTD）和剂量限制性毒性（DLT），以便为此类患者提供适当的帕唑帕尼给药建议。 另一个目标是记录与帕唑帕尼治疗相关的任何抗肿瘤活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this Phase I, NCI UO1 supported protocol is to establish the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of pazopanib in groups of patients with advanced cancer and varying degrees of hepatic dysfunction (mild, moderate, and severe) in order to provide appropriate dosing recommendations for pazopanib in such patients. Another goal will be to document any antitumor activity associated with pazopanib treatment.